Archer Materials Limited has developed a next generation biochip fabrication to better detect and control disease samples on a single graphene field effect transistor ("gFET") design. The gFET design also has functional surfaces and components, for both the sensor and control of the biochip platform. There is also an integration of gFET design components that allow for the real-time fine tuning and control of the electronic properties of the graphene.

This has the potential advantage of biosensors that are re-usable, leading to an extended device lifetime. In addition, Archer has improved its biochip system platform testing capabilities to develop a more accurate sensor. The upgraded automated testing platform conducts both control software and readout hardware with improved efficiency.

The software is also progressing towards automated data analysis, so end users can extract high quality data. This new more complex gFET design complements the proof-of-concept biosensing gFET announced on 13 July 2023. The earlier design was submitted to a commercial foundry for a Multi-Project Wafer run, with the completed devices expected to be delivered by the end of 2023.

The new advanced device designs which are the subject of this announcement have now been submitted to a foundry in the Netherlands for a whole wafer run (the previous 'simpler' design was submitted to a foundry in Germany for a Multi- Project Wafer ("MPW") run). An MPW is where Archer's device design is imprinted on a small area of a wafer with the designs of other companies on the same wafer. The new more complex gFet design will be fabricated all over one, stand-alone four-inch wafer.

The new advanced gFET device design and whole wafer run in a commercial foundry is an example of how Archer is now moving towards a streamlined commercialization model that closely aligns to the 'fabless' model (i.e. Archer focuses on designing and developing its chips and outsources the manufacturing to specialized foundries). The new gFET device designs and related processes form the basis of intellectual property that is 100% owned by Archer.